Atalanta Therapeutics Announces Leadership Transitions
BOSTON--(BUSINESS WIRE)-- Atalanta Therapeutics, a biotechnology company pioneering RNA interference (RNAi) for the treatment of intractable neurological diseases, announced today that Joanne Kotz has been named Chief Executive Officer and a member of the Board of Directors, succeeding Alicia Secor, who has stepped down as part of a planned transition to pursue other opportunities. The company also announced the appointment of Douglas Pagán as Chief Financial Officer & Chief Operating Officer, succeeding Jeffrey Young.
Additionally, Bob D. Brown, an industry veteran with extensive RNAi drug discovery and development experience, has joined the company's Scientific Advisory Board to advise as the company advances its innovative pipeline into the clinic.
"I want to thank Alicia for her extraordinary leadership of the company from formation to the cusp of entry into the clinic, as well as her continued role as an advisor through this transition,' said Dr. Stephen Knight, President and Senior Managing Partner of F-Prime and a member of the Atalanta Board of Directors. 'We are delighted to have Joanne lead Atalanta's next stage. Joanne is an accomplished leader who has demonstrated the ability to advance innovative platforms and pipelines through the transition to clinical stage, and has optimized company value creation through strong financings, partnerships and strategic transactions.'
'I'm thrilled to be joining Atalanta, which is pioneering the effort to bring RNAi therapies to patients living with devastating neurological diseases,' said Dr. Kotz. 'I am passionately committed to Atalanta's mission to deliver life-transforming therapies to patients and look forward to working with the team to transition our first programs into the clinic as we work to realize the full therapeutic potential of Atalanta's innovative di-siRNA platform.'
'Over the past six years we've made incredible scientific progress at Atalanta. I'm proud of all that we've been able to accomplish together and thank the Board and team for their support and dedication to our mission,' said Ms. Secor. 'The transition from research to clinical stage is a critical time for any biotech, and Joanne's leadership and experience is ideally suited to guide Atalanta's continued progress towards our mission of delivering RNAi medicines to patients living with severe neurological diseases.'
Dr. Kotz brings to Atalanta extensive executive experience, including most recently as cofounder and CEO of Jnana Therapeutics. She led the company from an early discovery platform stage through the transition to clinical stage. Jnana was acquired by Otsuka Pharmaceutical in 2024 for ~$1 billion following the demonstration of positive clinical proof of concept for the company's lead rare disease program. Prior to Jnana, Dr. Kotz held leadership roles at FBRI, F-Prime Capital's initiative to enable therapeutic breakthroughs in Alzheimer's disease and related brain disorders, and at the Broad Institute. She is a member of the Board of Directors of the Chordoma Foundation. Dr. Kotz received her Ph.D. in chemistry from the University of California, Berkeley and a B.S. in chemistry from the University of Florida. She conducted postdoctoral research at Genentech and at the Necker Children's Hospital in Paris.
Mr. Pagán brings to Atalanta more than two decades of experience in finance, investor relations, and capital formation across both public and venture-backed biopharmaceutical companies. Prior to joining Atalanta, he served as Chief Financial Officer and Chief Operating Officer at Jnana Therapeutics, where he was instrumental in securing the company's $107 million Series C financing heading into the clinic, and the subsequent ~$1 billion acquisition by Otsuka Pharmaceutical. Prior to Jnana, Mr. Pagán was Chief Financial Officer at the RNAi company Dicerna Pharmaceuticals, where he oversaw the 2021 sale of the company to Novo Nordisk for $3.3 billion. He has previously held leadership roles at Acceleron and Biogen and has served on the Board of Directors of the biotech companies Ziopharm Oncology and Timberlyne Therapeutics. Mr. Pagán holds an MBA from Columbia Business School and a BSE in chemical engineering from Princeton University.
Dr. Brown brings more than 30 years of experience in RNAi and oligonucleotide research and development, including from discovery through drug approval and across a wide range of clinical indications and regulatory jurisdictions. Most recently, Dr. Brown served as Chief Scientific Officer and Executive Vice President of R&D at Dicerna Pharmaceuticals, an RNAi-focused therapeutics company that was acquired by Novo Nordisk. At Novo, he served as President and Head of the Dicerna Transformation Research Unit and SVP. Prior to Dicerna, Dr. Brown held various R&D leadership positions at Genta, a clinical-stage antisense oligonucleotide therapeutics company, and previously was a co-founder of Oasis Biosciences, which was acquired by Gen-Probe. Dr. Brown earned a Ph.D. in molecular biology from the University of California, Berkeley and B.S. degrees in chemistry and biology from the University of Washington, Seattle.
About Atalanta Therapeutics
Atalanta Therapeutics is a biotechnology company developing treatments for intractable diseases of the central nervous system using RNA interference. Atalanta's unique platform of divalent small interfering RNA (di-siRNA) is designed to enable durable, selective gene silencing throughout the brain and spinal cord. Atalanta is advancing a wholly owned pipeline of disease-modifying programs for Huntington's disease, genetic epilepsy, severe chronic pain, and other neurological diseases in addition to partnered programs as part of a strategic collaboration with Genentech. Atalanta is headquartered in Boston, Mass. For more information, visit www.atalantatx.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
36 minutes ago
- Business Wire
Nine Dean Appoints Andrew Kassoy, Impact Pioneer, as Chairman Emeritus
NEW YORK--(BUSINESS WIRE)--Nine Dean, a holding company that partners with great businesses to drive long-term value for all stakeholders, today announced the appointment of founding team member Andrew Kassoy as Chairman Emeritus, effective immediately. This recognition reflects Kassoy's significant contributions as a valued partner, collaborator, and friend throughout the conception and launch of Nine Dean. Throughout Nine Dean's development, Kassoy has consistently brought a thoughtful perspective, challenging convention and encouraging innovative thinking around business structure and impact. His commitment to shared prosperity and sustainable growth inspires the Nine Dean team to approach opportunities holistically, and with a focus on enduring, inclusive value creation. 'I know I speak for our entire team when I say that Andrew profoundly influences the way we think about growth, innovation, and our responsibility to all those connected to Nine Dean,' said Aren LeeKong, CEO of Nine Dean. 'As both a partner and a friend, Andrew's thoughtful approach and dedication to building businesses that create lasting, shared value has left a meaningful mark on all of us. We're proud to recognize him as Chairman Emeritus and deeply appreciate the foundation he's helped us build.' In addition to his work at Nine Dean, Kassoy is a Co-Founder of B Lab, a non-profit building a global movement to redefine success in business so that all companies compete not just to be best in the world, but best for the world, creating a shared and durable prosperity for all. Before leaving the private sector to found B Lab, Kassoy spent 16 years in the private equity industry, as a Partner at MSD Real Estate Capital, an investment vehicle for Michael Dell, as Managing Director in Credit Suisse First Boston's Private Equity Department, and as a founding partner of DLJ Real Estate Capital Partners. He also served as a Board Member of Echoing Green, as a Skoll Awardee for Social Entrepreneurship, on the U.S. working group of the G8 Social Impact Investing Task Force, and on the Forbes Impact 30 list of leading social entrepreneurs. Kassoy's appointment as Chairman Emeritus follows Nine Dean's launch on June 3, 2025. The growing firm looks forward to announcing its full Board of Directors in due course. About Nine Dean Nine Dean is a holding company that acquires lower-middle market businesses and positions them for enduring success through operational excellence and investing in their most valuable asset: employees. The firm's permanent holding company structure aligns all stakeholders and invests in employees to drive profitability across its operating companies, focused on long-term value and sustainable growth. Based in New York City, Nine Dean was founded by a seasoned team with deep expertise across all facets of business ownership, including entrepreneurial ventures, capital markets, credit, private equity, and operations. More information on Nine Dean is available at .
Business Wire
42 minutes ago
- Business Wire
Veolia Opens One of the Largest PFAS Treatment Plants in the U.S., Delivering High-Quality Drinking Water to Over 100,000 Delaware Residents
WILMINGTON, Del.--(BUSINESS WIRE)--At a time when water is more vital than ever for public health and environmental protection, Veolia has built one of the largest PFAS treatment systems in the United States and the largest of its kind in the Northeast. The Stanton Water Treatment Plant will remove regulated PFAS compounds from drinking water and ensure high-quality drinking water for over 100,000 residents, fully meeting the U.S. Environmental Protection Agency's (EPA) PFAS regulations. It establishes a replicable model for cost-effective PFAS treatment projects in water systems globally. Veolia has built one of the largest PFAS treatment systems in the United States and the largest of its kind in the Northeast, ensuring high-quality drinking water for over 100,000 residents Share The $35 million facility is in addition to 33 existing PFAS treatment systems Veolia already operates for water customers in the United States. Veolia will continue to install treatment systems to achieve PFAS treatment at more than 100 water production sites in the country in the coming years, which will help secure high-quality drinking water for almost 2 million people and comply with regulations in the most cost-effective way possible. Veolia's experience meeting the challenge in America has built a strong foundation to do it across the globe. The successful delivery of PFAS treatment for drinking water in Delaware exemplifies how Veolia's BeyondPFAS offering of end-to-end solutions can manage PFAS from testing through treatment and responsible disposal. About the plant Veolia began designing the Stanton PFAS system in early 2022, ahead of the new EPA regulations for some PFAS levels in drinking water, and worked methodically to deliver a state-of-the-art plant that minimized construction costs and left maximum flexibility for the future. It took three years to design and build the 17,600-square-foot facility which features 42 large vessels, each 22 feet high and filled with 40,000 pounds of granular activated carbon. The vessels are designed and optimized for the carbon material to adsorb regulated PFAS compounds from up to 30 million gallons of water per day that enters the plant from two nearby rivers. The massive vessels were installed first and the building was constructed around them, requiring precise coordination and timing during the construction process. The plant includes a laboratory to continually test new filtration media and treatment methods, providing additional flexibility and cost savings in the future. At a ribbon-cutting ceremony today, Veolia leaders were joined by Delaware elected officials and community leaders to celebrate the achievement, which went from the drawing board to a working treatment plant in three years. Estelle Brachlianoff, CEO of Veolia, said: ' In line with our GreenUp strategic program, this major infrastructure milestone highlights Veolia's strong commitment to delivering environmental security solutions to communities worldwide. Tackling micropollutants lies at the heart of our mission, and Veolia is proud to lead the way in testing, treating and responsibly disposing of regulated PFAS contaminants. For the 100,000 people who rely on high-quality water from Veolia in Delaware, the Stanton PFAS treatment system is a generational improvement in public health and environmental protection that will strengthen communities and create opportunities long into the future. ' ' PFAS contamination poses a serious threat to public health, and addressing it at the source is essential,' said Delaware Governor Matt Meyer. ' The Stanton Water Treatment Plant will play a vital role in tackling this challenge by treating PFAS on the front end of the water system. Veolia's leadership in developing one of the largest treatment facilities in the country reflects a strong commitment to proactive public health protection and underscores our administration's dedication to ensuring clean, safe water for Delawareans.' Karine Rougé, CEO of Municipal Water for Veolia in North America, said: ' I'm inspired by how swiftly and effectively Veolia responded to the PFAS challenge in Delaware through this state-of-the-art facility, which now sets a global standard. The lessons from this project will help Veolia deploy similar water quality improvements faster, more efficiently and more effectively. We're proud of our team for designing and building this vital project so quickly and so well, and we're thrilled that so many of our customers are able to benefit from their tireless work.' ABOUT VEOLIA IN NORTH AMERICA Veolia in North America is the top-ranked environmental company in the United States for three consecutive years, and the country's largest private water operator and technology provider as well as hazardous waste and pollution treatment leader. It offers a full spectrum of water, waste, and energy management services, including water and wastewater treatment, commercial and hazardous waste collection and disposal, energy consulting and resource recovery. Veolia helps commercial, industrial, healthcare, higher education and municipality customers throughout North America. Headquartered in Boston, Veolia has more than 10,000 employees working at more than 350 locations across North America. ABOUT VEOLIA Veolia group aims to become the benchmark company for ecological transformation. Present on five continents with 215,000 employees, the Group designs and deploys useful, practical solutions for the management of water, waste and energy that are contributing to a radical turnaround of the current situation. Through its three complementary activities, Veolia helps to develop access to resources, to preserve available resources and to renew them. In 2024, the Veolia group provided 111 million inhabitants with drinking water and 98 million with sanitation, produced 42 million megawatt hours of energy and treated 65 million tons of waste. Veolia Environnement (Paris Euronext: VIE) achieved consolidated revenue of 44.7 billion euros in 2024. The information contained herein is based on the Veolia group's understanding and know-how of the scientific, regulatory and technical fields discussed herein as of the time of publication. No contractual undertaking or offer is made on the basis hereof and no representation or warranty is given as to the accuracy, completeness or suitability for the purpose of the relevant information.
Business Wire
42 minutes ago
- Business Wire
Vicinity Energy Kicks off Electrification Plans in Grand Rapids
GRAND RAPIDS, Mich.--(BUSINESS WIRE)-- Vicinity Energy, a decarbonization leader with the nation's largest portfolio of district energy systems, has officially kicked off its Grand Rapids electrification plans by commencing the installation of its newest electric boiler. Vicinity will install the 9MW electric boiler at its Grand Rapids facility, marking a key milestone in the company's Clean Energy Future commitment to reaching net zero carbon emissions across all of its operations by 2050. When the electric boiler enters service in 2026, over 100 of Vicinity's customers in Grand Rapids will have access to carbon-free thermal energy instantly Share U.S. Representative Hillary Scholten (MI-3) commemorated the milestone at Vicinity's Grand Rapids facility, along with local business leaders and energy advocates. 'We are proud to see Vicinity, a long-standing energy partner in Grand Rapids, launch its innovative eSteam TM right here in the city,' said Grand Rapids Mayor David LaGrand. 'This project will bring locally generated, carbon-free steam to our downtown businesses, supporting Grand Rapids' commitment to sustainability, clean energy, and a resilient future.' Vicinity Energy received a grant exceeding $2 million from the Michigan Public Service Commission (MPSC) as part of the Renewable Energy and Electrification Infrastructure Enhancement and Development (EIED) program. This funding supports the installation of the 9MW electric boiler at Vicinity's downtown Grand Rapids facility, marking the first new boiler addition in 60 years at the facility. The project aims to produce carbon-free eSteam TM to support the decarbonization of Grand Rapids, aligning with the MI Healthy Climate Plan's goals to reduce greenhouse gas emissions and transition toward carbon neutrality. 'Our work towards carbon-free, clean energy is critically important to not only our own goals, but the goals of our state and local partners across the country. Here in Grand Rapids with the installation of this electric boiler, we will enable a seamless conversion to carbon-free eSteam TM for our customers,' said Vicinity Energy CEO Kevin Hagerty. When the electric boiler enters service in 2026, over 100 of Vicinity's customers in Grand Rapids will have access to carbon-free thermal energy instantly. Click here to read more about Vicinity's district energy systems and its commitment to innovation and the environment. About Vicinity Energy Vicinity Energy is the largest owner and operator of district energy systems dedicated to decarbonizing its operations and investing in innovative renewable thermal energy technologies to offer carbon-free eSteam™ to its customers. Operating 19 district energy systems in 12 cities, Vicinity delivers reliable and sustainable steam, hot water, and chilled water to 250 million square feet of building space nationwide. As Vicinity advances its electrification efforts across its locations, the goal to achieve net zero by 2050 is more than a commitment—it's a mission. Learn more about Vicinity's vision for a clean energy future at
